Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTorsak Bunupuradahen_US
dc.contributor.authorAzar Kariminiaen_US
dc.contributor.authorKwai Cheng Chanen_US
dc.contributor.authorReshmie Ramautarsingen_US
dc.contributor.authorBui Vu Huyen_US
dc.contributor.authorNing Hanen_US
dc.contributor.authorRevathy Nallusamyen_US
dc.contributor.authorRawiwan Hansudewechakulen_US
dc.contributor.authorVonthanak Saphonnen_US
dc.contributor.authorVirat Sirisanthanaen_US
dc.contributor.authorKulkanya Chokephaibulkiten_US
dc.contributor.authorNia Kurniatien_US
dc.contributor.authorNagalingeswaran Kumarasamyen_US
dc.contributor.authorNik Khairulddin Nik Yusoffen_US
dc.contributor.authorKamarul Razalien_US
dc.contributor.authorSiew Moy Fongen_US
dc.contributor.authorAnnette H. Sohnen_US
dc.contributor.authorPagakrong Lumbiganonen_US
dc.description.abstractBackground: There are limited data on treatment-related anemia in Asian HIV-infected children. Methods: Data from Asian HIV-infected children aged <18 years on first-line highly active antiretroviral therapy (HAART) were used. Children who had pre-existing severe anemia at baseline were excluded. Anemia was graded using the United States Division of AIDS (DAIDS) 2004 table. Potential risk factors for severe anemia were assessed by logistic regression. Results: Data from 1648 children (51.9% female, 62.8% World Health Organization (WHO) stage 3/4) were analyzed. Median (interquartile range) age was 6.8 (3.7-9.6) years, CD4% was 9 (3-16)%, and plasma HIV-RNA was 5.2 (4.7-5.6) log10copies/ml at HAART initiation in those with available testing. The most common regimens were stavudine/lamivudine/nevirapine (42%) and zidovudine/lamivudine/nevirapine (25%). Severe anemia was identified in 47 (2.9%) children after a median time of 6 months after HAART initiation, with an incidence rate of 5.4 per 100 child-years. Mild anemia or moderate anemia at baseline (p = 0.024 and p = 0.005, respectively), previous or current use of zidovudine (p < 0.0001 and p = 0.013, respectively), and male sex (p = 0.008) were associated with severe anemia. Higher weight-for-age z-score (p = 0.004) was protective. Conclusions: The incidence of severe anemia in Asian HIV-infected children after HAART initiation was low and mainly occurred during the first few months after HAART initiation. Mild to moderate anemia at baseline and using zidovudine were independent risk factors for the development of severe anemia. © 2013 International Society for Infectious Diseases.en_US
dc.titleIncidence and predictors of severe anemia in Asian HIV-infected children using first-line antiretroviral therapyen_US
article.title.sourcetitleInternational Journal of Infectious Diseasesen_US
article.volume17en_US HIV Netherlands Australia Thailand Research Collaborationen_US of New South Wales (UNSW) Australiaen_US Pulau Pinangen_US Medical Centre, University of Amsterdamen_US Hospital of Pediatrics Hanoien_US Ditan Hospitalen_US Prachanukroh Hospitalen_US Pediatric Hospitalen_US Mai Universityen_US Universityen_US of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US Gaitonde Centre for AIDS Research and Educationen_US Raja Perempuan Zainab IIen_US Lumpur Hospitalen_US Likasen_US Asia/amfAR-The Foundation for AIDS Researchen_US Kaen Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.